


From: King Kimchi <consulting012345@gmail.com>
Sent: Mon 10/5/2020 8:36:14 PM (UTC)
To: compliance <compliance@Safechain.com>, Charles Boyd
<CharlesB@Safechain.com>, Abbie Divilio <AbbieD@Safechain.com>
Attachment: CDGXKA.pdf

Please let me know if it's all good to go



SCSRELATIVITY_0001433889

GX 310.0001

SAFE CHAIN SOLUTIONS, LLC

Drug Supply Chain Security Act Document**(TI) Transaction Information**

Drug Name, Strength, Dosage Form, Container Size:
BIKTARVY 30CT

NDC: 61958-2501-01

Reference Number: INV 6901Document Type: INVOICEReference Date: 09/28/2020

Lot Number	Quantity	Unique Serial #
CDGXKA	5	

(TH) Transaction History

Manufacturer's Name: Gilead Sciences, Inc.
Manufacturer's information: 333 Lakeside Drive, Foster City, CA 94404

SOLD TO:

Name: Rochester Drug Co-Op Inc
Address: 116 Lehigh Dr #3013
Fairfield, NJ 07004

Date Purchased & Ref : 09/04/18 PO#R2367

SHIPPED TO:

Name: Rochester Drug Co-Op Inc
Address: 116 Lehigh Dr #3013
Fairfield, NJ 07004

Date Received & Ref : 09/04/18

SOLD TO:

Name: Instacare Pharmacy DBA Brookville RX
Address: 235-20 147th Ave Rosedale, NY 11422

Date Purchased & Ref : 10/15/18 PO#001IC545

SHIPPED TO:

Name: Instacare Pharmacy DBA Brookville RX
Address: 235-20 147th Ave Rosedale, NY 11422

Date Received & Ref : 10/15/18

SOLD TO:

Name: BOULEVARD 9229 LLC
Address: 9229 QUEENS BLVD STE
11 REGO PARK, NY 11374

Date Purchased & Ref : 09/15/20 PO#01209744

SHIPPED TO:

Name: BOULEVARD 9229 LLC
Address: 9229 QUEENS BLVD STE
11 REGO PARK, NY 11374

Date Received & Ref : 09/15/20

SOLD TO:

Name: SAFE CHAIN SOLUTIONS, LLC
Address: 822 CHESAPEAKE DR
CAMBRIDGE MD 21613

Date Purchased & Ref : 09/28/20 PO#9311

SHIPPED TO:

Name: SAFE CHAIN SOLUTIONS, LLC
Address: 822 CHESAPEAKE DR
CAMBRIDGE MD 21613

Date Received & Ref : 09/28/20

SOLD TO:

Name:
Address:

Date Purchased & Ref :

SHIPPED TO:

Name:
Address:

Date Received & Ref :

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
(B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
(C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
(D) did not knowingly ship a suspect or illegitimate product;
(E) had systems and processes in place to comply with verification requirements under section 582;
(F) did not knowingly provide false transaction information; and
(G) did not knowingly alter the transaction history.